Geriatric Considerations in Low-Dose Ketamine Therapy

Low dose ketamine therapy for adults aged 65 and older may be considered in selected cases, but it requires careful clinical screening, conservative dosing, cardiovascular observation, and attention to cognition and fall risk. The evidence for older adults is limited, especially for repeated IV ketamine treatment, so decisions should be individualized by a qualified clinician with the patient and caregiver when appropriate.

Ketamine is an anesthetic medication that can produce short-term changes in blood pressure, heart rate, perception, and thinking at subanesthetic doses. Older adults often have more cardiovascular disease, medication use, frailty, and cognitive impairment, which can affect both treatment tolerability and the monitoring plan.

Why age can change the ketamine treatment plan

Aging can change how medicines are distributed, metabolized, and tolerated. Older adults may also have lower physiologic reserve, multiple prescriptions, orthostatic blood pressure changes, or conditions that make transient dissociation and sedation harder to manage.

Ketamine is metabolized in the liver and its metabolites are cleared largely through the kidneys. Reduced hepatic blood flow, changes in body composition, lower albumin in some patients, and reduced kidney function may affect exposure or recovery time, although the exact clinical effect varies from person to person. This is one reason clinicians commonly favor slower, individualized titration rather than assuming a standard adult regimen fits every older patient.

For a broader overview of dose formats and clinical considerations, see this guide to ketamine dosage. Readers can also review how long ketamine effects may last when planning transportation and recovery time.

Cardiovascular screening and monitoring

Ketamine can temporarily raise blood pressure and heart rate. That effect matters more when a patient has uncontrolled hypertension, coronary artery disease, heart failure, arrhythmia, prior stroke, or symptoms that need medical assessment before treatment.

The U.S. Food and Drug Administration prescribing information for Spravato, an intranasal esketamine product, states that blood pressure should be assessed before dosing and monitored after administration because substantial increases can occur. The FDA-approved prescribing information also describes observation requirements and contraindications specific to that product. Those instructions should not be treated as a substitute for an IV ketamine protocol, but they illustrate why monitored administration is important.

According to the U.S. Centers for Disease Control and Prevention, nearly 70% of adults age 65 and older had hypertension during August 2021 to August 2023. CDC data on hypertension prevalence supports the need for careful baseline assessment in this age group.

A geriatric assessment may include baseline vital signs, a cardiovascular history, a medication review, and an electrocardiogram when the treating clinician considers it appropriate. During treatment, the level of observation should reflect the route, dose, setting, comorbidities, and local protocol. Patients should not drive after treatment and should arrange a responsible adult to assist with transportation and recovery.

For related context, read our overview of cardiovascular monitoring during ketamine treatment.

Cognition, delirium, and fall risk

Baseline cognition matters because ketamine can temporarily affect attention, memory, perception, and coordination. Mild cognitive impairment or dementia does not automatically answer whether treatment is appropriate, but it can make informed consent, symptom tracking, and detection of adverse effects more difficult.

A clinician may use a brief cognitive screen, collateral information from a caregiver, and a review of recent changes in memory or daily function. The Montreal Cognitive Assessment is a commonly used screening tool for cognitive impairment, but a screening score is not a diagnosis and should be interpreted in clinical context.

Delirium is an acute change in attention and awareness that is more common in medically vulnerable older adults. Risk may be higher with pre-existing cognitive impairment, dehydration, acute illness, sensory impairment, sleep disruption, or medicines with sedating or anticholinergic effects. If new confusion develops during a treatment course, clinicians may need to pause treatment and evaluate reversible causes.

Fall prevention is practical, not optional. Patients should receive help when standing or walking after treatment, use mobility aids when needed, and leave only after the treating team determines that recovery is adequate. A caregiver can help identify interval changes in cognition, behavior, gait, or functioning.

What the evidence says for older adults

The evidence base is smaller for adults age 65 and older than for younger adults. Many ketamine depression studies enrolled limited numbers of older participants or did not report detailed age-specific outcomes.

One randomized trial evaluated intranasal esketamine plus a newly initiated oral antidepressant in adults 65 and older with treatment-resistant depression. The trial did not meet its primary endpoint for the overall study population. The TRANSFORM-3 publication provides the study details and should be read alongside the FDA-approved product labeling when considering intranasal esketamine.

Evidence from IV ketamine studies and observational reports suggests that some older adults may experience benefit, but these data do not establish that any particular dose, infusion duration, or schedule is best for all geriatric patients. The key practical point is that a favorable response in younger adults cannot be assumed to translate directly to an older person with different medical risks.

For people researching depression treatment optionsthis guide to next steps for treatment-resistant depression can help frame questions for a treating clinician.

How clinicians may adapt a plan for an older patient

A cautious plan starts with fit, not a fixed number. A treating clinician may consider a lower starting exposure or slower administration when clinical factors suggest increased sensitivity, then reassess tolerability and benefit before making changes. The appropriate approach depends on the route of administration, indication, comorbidities, concurrent medicines, and the facility's clinical protocol.

Medication reconciliation is especially important. Sedatives, opioids, benzodiazepines, blood pressure medicines, and drugs with anticholinergic effects can affect alertness, balance, blood pressure, or interpretation of symptoms. Patients should not stop or change prescribed medicines on their own.

Caregivers should be included when the patient agrees, particularly when there are memory concerns or a history of falls. They can help the treatment team recognize changes that may not be obvious during a brief visit.

See monitoring and assessment considerations for additional questions that may be relevant during a ketamine treatment course.